CutisPharma in pact with DRL

The partnership with CutisPharma will further enhance and strengthen the R&D portfolio in bringing good health to millions in the country," Deepak Sapra, vice-president and global head, DRL, said.TNN | April 06, 2016, 09:00 IST

Hyderabad: US-based specialty pharmaceutical company CutisPharma on Tuesday announced that it has entered into an active pharmaceutical ingredient (API) supply and joint development agreements with Hyderabad-based pharma giant Dr Reddy's Laboratories to advance several programs in its R&D portfolio.

"We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with CutisPharma will further enhance and strengthen the R&D portfolio in bringing good health to millions in the country," Deepak Sapra, vice-president and global head (custom pharmaceutical services business), DRL, said. CutisPharma CEO Neal Muni said the partnership will have strategic benefits for both parties. The partnership with DRL will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval, the company said.